Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in patients with metastatic squamous non–small cell lung cancer (NSCLC)
On June 4, Gregory H. Reaman, MD, FASCO, professor of pediatrics at George Washington University School of Medicine and Health Sciences, will receive the Pediatric Oncology Award for his outstanding leadership and achievements in the field.
ASCO’s Partners in Progress Award, to be presented June 4, honors an individual whose patient advocacy has impacted public awareness about cancer or resulted in additional support—either legislatively or fiscally—for cancer research, treatment, prevention, or care.
Use and cost of systemic therapy for metastatic colorectal cancer is significantly higher for patients in western Washington state in the United States compared to those in British Columbia, Canada, with no significant differences in overall survival.
Analyzing cell-free DNA (cfDNA) circulating in plasma or serum can help oncologists determine the genotype of tumors noninvasively to guide treatment decisions and may eventually allow them to monitor treatment response, predict recurrence, and screen for cancer.
“We are at a turning point in the history of cancer,” said Scott Gottlieb, MD, commissioner of the U.S. Food and Drug Administration (FDA), addressing the crowded room of ASCO attendees during the Opening Session on June 2.
With recent approvals of pembrolizumab and nivolumab for the treatment of refractory deficient mismatch repair (dMMR) metastatic colorectal cancer (CRC), immunotherapy has made its way into the field of gastrointestinal oncology.